Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR3 over exp |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR3 Antibody FGFR3 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR3 over exp | glioblastoma | sensitive | U0126 | Preclinical | Actionable | In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells over-expressing Fgfr3 in culture (PMID: 23298836). | 23298836 | |
FGFR3 over exp | urinary bladder cancer | sensitive | FGFR3 Inhibitor | SU5402 | Preclinical | Actionable | In a preclinical study, SU5402 inhibited growth of bladder cancer cells over expressing wild-type FGFR3 in culture (PMID: 21119661). | 21119661 |
FGFR3 over exp | multiple myeloma | sensitive | FGFR3 Antibody | Vofatamab | Phase I | Actionable | In a Phase I trial, Vofatamab (B-701) demonstrated safety and resulted in stable disease in 42% (6/14) of multiple myeloma patients overexpressing FGFR3 (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029). | detail... |
FGFR3 over exp | head and neck squamous cell carcinoma | sensitive | FGFR Inhibitor (Pan) | Rogaratinib | Preclinical | Actionable | In a preclinical study, Rogaratinib (BAY 1163877) inhibited tumor growth in a head and neck squamous cell carcinoma xenograft model with FGFR3 overexpression (Cancer Res August 1, 2015 75:772). | detail... |
FGFR3 over exp | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | Rogaratinib | Phase I | Actionable | In a Phase I trial, treatment with Rogaratinib (BAY 1163877) was well-tolerated and resulted in objective response rate (ORR) of 15% (15/100) in patients with FGFR1, FGFR2, or FGFR3-overexpressing advanced solid tumors, including urothelial cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer, and led to an ORR of 67% (10/15) in patients with FGFR overexpression, but without an FGFR genetic aberration (PMID: 31405822). | 31405822 |
FGFR3 over exp | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Cell culture | Actionable | In a preclinical study, PRN1371 inhibited proliferation in transformed cells overexpressing wild-type FGFR3 in culture (PMID: 28978721). | 28978721 |
FGFR3 over exp | urinary bladder cancer | sensitive | FGFR Inhibitor (Pan) | Dovitinib | Phase II | Actionable | In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 8% (1/13) of non-muscle invasive bladder cancer patients over expressing FGFR3 (J Clin Oncol 34, 2016 (suppl; abstr 4526)). | detail... |
FGFR3 over exp | lung squamous cell carcinoma | no benefit | FGFR Inhibitor (Pan) | Rogaratinib | Phase II | Actionable | In a Phase II trial, Rogaratinib (BAY 1163877) treatment did not result in improved progression-free survival (PFS) of metastatic lung squamous cell carcinoma patients with overexpression of FGFR1, FGFR2, or FGFR3, as only 10% (1/10) of patients achieved 6-month PFS, further clinical development of this agent was halted (J Clin Oncol 39, no. 15_suppl (May 20, 2021) e2119; NCT03762122). | detail... |
FGFR3 over exp | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | LY2874455 | Preclinical | Actionable | In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693). | 21900693 |
FGFR3 over exp | transitional cell carcinoma | sensitive | FGFR3 Inhibitor | AZ8010 | Preclinical | Actionable | In a preclinical study, AZ8010 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148). | 22869148 |
FGFR3 over exp | transitional cell carcinoma | sensitive | FGFR3 Inhibitor | AZD4547 | Preclinical | Actionable | In a preclinical study, AZD4547 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148). | 22869148 |
FGFR3 over exp | urinary bladder cancer | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Pdx | Actionable | In a preclinical study, treatment with Truseltiq (infigratinib) led to improved progression-free survival in a patient-derived xenograft (PDX) model of bladder cancer with FGFR3 over expression (PMID: 26270481). | 26270481 |
FGFR3 over exp | urinary bladder cancer | sensitive | Dactolisib + Sorafenib | Preclinical - Pdx | Actionable | In a preclinical study, the combination of BEZ235 and Nexavar (sorafenib) resulted in improved progression-free survival in an FGFR3-over expressing patient-derived xenograft (PDX) model of bladder cancer with secondary resistance to BGJ398 due to reactivation of downstream signaling, as evidenced by increased activation of Akt and Erk (PMID: 26270481). | 26270481 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Recruiting | ITA | FRA | BEL | 1 |
NCT03410693 | Phase II | Docetaxel Vinflunine Paclitaxel Rogaratinib | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 21 |
NCT03473756 | Phase Ib/II | Atezolizumab Atezolizumab + Rogaratinib | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUT | 2 |
NCT04040725 | Phase II | Rogaratinib | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | Withdrawn | 0 | |
NCT03517956 | Phase I | Copanlisib + Rogaratinib | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) | Completed | USA | ESP | DEU | BEL | 2 |